Sun Pharma’s US subsidiary, Taro Pharmaceutical Industries, has issued a recall for over 17,000 units of Ciclopirox Shampoo due to manufacturing problems, as stated by the US Food and Drug Administration (USFDA). The recall was initiated on December 9, with the reason cited as “failed impurity/degradation specifications” in the latest Enforcement Report by the USFDA.
Taro Pharmaceutical Industries’ nationwide recall of 17,664 units of the antifungal medication is classified as a Class II recall by the USFDA. A Class II recall signifies that the product in question could potentially cause temporary or medically reversible health issues, with minimal chances of severe adverse health outcomes.
Sun Pharma, the parent company of Taro, acquired the Israel-based Taro Pharmaceutical Industries for $347.73 million last year. Specializing in dermatology, Taro offers a broad range of prescription and over-the-counter products to consumers.
Sun Pharmaceutical Industries, a major player in the Indian pharmaceutical sector, holds a significant market share in formulations. The company is a key exporter to the US market, recording revenue of Rs 14,478 crore in the second quarter of FY26. Despite a 4.1% decline in formulation sales in the US, the company reported a 2.56% year-on-year increase in net profit to Rs 3,118 crore.
